In a statement, Bristol-Myers Squibb Co and Eisai Co said, they had entered into an agreement to jointly develop and market an experimental cancer drug worth up to $3.10 billion. Bristol-Myers would pay $650 million, including for research and development… Read More ›
Susanne Schaffert will be replacing Liz Barrett who will return to the U.S. to head a U.S. biotech firm. Swiss pharmaceutical giant Novartis has stated, it has appointed Susanne Schaffert, a veteran, as the head of its oncology business. She… Read More ›
The deal, one of the largest in the pharma industry, will place Takeda Pharma into the top ranks of global drugmakers. On Tuesday, in a strategic move Japan’s Takeda Pharma stated it has agreed to acquire London-listed Shire for $61.50… Read More ›
Ignyta’s precision drugs and diagnostic portfolio will help Roche increase its global footprint in the oncology department. On Friday, U.S. cancer drugmaker Ignyta Inc and Swiss drugmaker Roche disclosed that the Swiss pharmaceutical giant will acquire U.S. drugmaker for $1.7… Read More ›
manageria.biz 